Iain McGregor is Professor of Psychopharmacology and Academic Director of the Lambert Initiative for Cannabinoid Therapeutics in the Brain and Mind Centre at the University of Sydney, Australia. Iain’s research is focused on the discovery of new medications for the treatment of disease and involves the full pipeline from medicinal chemistry, through cellular and animal models, to clinical trials. Iain has more than 350 peer-reviewed publications and multiple patents. The discoveries of his team around the use of oxytocin-like small molecules to treat addiction and social withdrawal led to the successful spinoff company Kinoxis Therapeutics.
The Lambert Initiative for Cannabinoid Therapeutics which was formed in 2015 with a gift of unprecedented generosity from the Lambert family to the University of Sydney. The Lambert Initiative, under Iain’s leadership, conducts world-leading research into the therapeutic benefits of cannabinoids in epilepsy, pain, cancer, addictions and mental health conditions. It has also developed a large library of proprietary small molecules through an in-house medicinal chemistry team. Iain was recently recognized with an award from the International Alliance for Cannabinoid Medicines (IACM) for his outstanding clinical research.
Recently Iain and his team have diversified into psychedelic research and are currently implementing a new research program around plant-based psychedelic drug discovery and a clinical trial of psilocybin in the treatment of eating disorders.